Predictive value of serum MMP-9, FABP5 combined with MRI for the efficacy and recurrence of primary liver cancer after percutaneous radiofrequency ablation
10.3760/cma.j.cn371439-20241030-00061
- VernacularTitle:血清MMP-9、FABP5联合MRI对原发性肝癌经皮穿刺射频消融术后疗效及复发的预测价值
- Author:
Xiaobin YANG
1
;
Jinquan JIANG
Author Information
1. 空军军医大学第一附属医院介入手术中心，西安 710032
- Keywords:
Liver neoplasms;
Radiofrequency ablation;
Matrix metalloproteinase 9;
Fatty acid binding protein 5;
Magnetic resonance imaging
- From:
Journal of International Oncology
2025;52(6):360-365
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the predictive value of serum matrix metalloproteinase-9 (MMP-9), fatty acid-binding protein 5 (FABP5) combined with MRI for the efficacy and recurrence of primary liver cancer after percutaneous radiofrequency ablation.Methods:A total of 192 patients with primary liver cancer who underwent percutaneous radiofrequency ablation treatment at the First Affiliated Hospital of Air Force Medical University from June 2022 to May 2023 were selected as the research subjects. MRI examination was performed within one week before the treatment, and the apparent diffusion coefficient (ADC) value was recorded. The enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of MMP-9 and FABP5 in the serum. According to the results of MRI examination, the ablation status of the lesions was determined, and the patients were divided into a complete ablation group ( n=157) and a residual lesion group ( n=35). Patients with completely ablated lesions were regularly followed up for one year, and their recurrence status was recorded. According to the recurrence of the patients, the patients were divided into a non-recurrence group ( n=115) and a recurrence group ( n=42). The levels of MMP-9 and FABP5 and the ADC values of the patients in the complete ablation group and the residual lesion group, as well as those in the non-recurrence group and the recurrence group, were compared. The receiver operator characteristic (ROC) curve was used to evaluate the predictive value of serum MMP-9 and FABP5 combined with MRI for the postoperative efficacy and recurrence of the patients. Results:The levels of serum MMP-9 and FABP5, and the ADC value of patients in the complete ablation group were (181.05±29.68) ng/ml, (7.95±1.82) μg/L, and (1.32±0.45) ×10 -3 mm 2/s, respectively, while those in the residual lesion group were (202.18±35.06) ng/ml, (9.56±2.39) μg/L, and (0.75±0.23) ×10 -3 mm 2/s, respectively. The levels of MMP-9 and FABP5 in the complete ablation group were significantly lower than those in the residual lesion group, and the ADC value was significantly higher than that in the residual lesion group, with statistically significant differences ( t=3.68, P<0.001; t=4.45, P<0.001; t=7.27, P<0.001). The areas under the curve (AUC) of serum MMP-9, FABP5, and ADC value alone in predicting the postoperative efficacy of patients were 0.68 (95% CI: 0.61-0.75), 0.75 (95% CI: 0.68-0.81), and 0.90 (95% CI: 0.85-0.94), respectively. The AUC of the combined prediction of these three was 0.94 (95% CI: 0.89-0.97), and the combined prediction of these three was superior to the individual prediction of MMP-9, FABP5, and ADC value ( Z=5.72, P<0.001; Z=4.84, P<0.001; Z=2.29, P=0.022). The levels of serum MMP-9 and FABP5, and the ADC value of patients in the non-recurrence group were (176.52±30.28) ng/ml, (8.69±1.92) μg/L, and (1.35±0.29) ×10 -3 mm 2/s, respectively, while those in the recurrence group were (201.85±28.72) ng/ml, (11.05±2.86) μg/L, and (1.14±0.12) ×10 -3 mm 2/s, respectively. The levels of serum MMP-9 and FABP5 of patients in the non-recurrence group were significantly lower than those in the recurrence group, and the ADC value was significantly higher than that in the recurrence group, with statistically significant differences ( t=4.70, P<0.001; t=5.93, P<0.001; t=4.55, P<0.001). The AUCs of serum MMP-9, FABP5, and ADC value alone in predicting the postoperative recurrence of patients were 0.74 (95% CI: 0.66-0.81), 0.90 (95% CI: 0.84-0.94), and 0.74 (95% CI: 0.66-0.80), respectively. The AUC of the combined prediction of these three was 0.95 (95% CI: 0.90-0.98), and the combined prediction of these three was superior to the individual prediction of MMP-9, FABP5, and ADC value ( Z=5.00, P<0.001; Z=3.03, P=0.002; Z=5.33, P<0.001) . Conclusions:The levels of serum MMP-9 and FABP5 in patients with primary liver cancer treated by percutaneous radiofrequency ablation in the complete ablation group are significantly lower than those in the residual lesion group, and the ADC value is significantly higher than that in the residual lesion group. The levels of serum MMP-9 and FABP5 of patients in the non-recurrence group are also significantly lower than those in the recurrence group, and the ADC value is also significantly higher than that in the recurrence group. The combined detection of serum MMP-9, FABP5 and MRI has a relatively high clinical value in predicting the efficacy and recurrence of patients after percutaneous radiofrequency ablation for liver cancer.
